will seek to develop a new product for the treatment of rhinitis under a licensing agreement with pharmaceutical firm Boehringer Ingelheim International GmbH, which is based in Germany.
Rhinitis is one of the most common forms of allergic conditions.
Inspire wants to develop an intranasal dosage form of epinastine, the active drug substance it is licensing. Inspire said it wants to begin testing of the drug later this year.
Terms of the deal were not disclosed.
Inspire paid Boehringer Ingelheim an upfront license fee, will fund development efforts, and pay royalties if the drug is approved. The agreement covers Canada and the United States.
Copyright 2024 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
